skip to navigation skip to content
 

Accelerate Plus

angioClast

angioClast is a UK and Ireland-based biotech startup company led by a group of young professionals from the University of Cambridge. We are developing products targeting Glioblastoma Multiforme, the most aggressive and incurable brain cancer, from both diagnostic and therapeutic perspectives. 

angioClast's business model is to license out a patent from the National Institute of Health through the NIH start-up exclusive licensing agreement, and harness the value of newly identified biomarkers of cancer-associated blood vessels. Antibodies against these markers form the basis for antibody-drug conjugates (ADCs) that will deliver and release drugs against glioblastoma in a highly specific manner. Detection of glioblastoma will be made possible through further formulation of the antibodies into an ELISA-based diagnostic toolkit that is more accurate and less invasive than conventional clinical practices.

Through innovative products for early detection and targeted therapy, angioClast's vision is to make Glioblastoma Multiforme a more treatable disease.

Cambridge Energy Partners

Cambridge Energy Partners sells renewable energy to large scale industrial operators in underdeveloped areas. As an independent power provider, our energy solutions enable our customers to reduce both operating costs and carbon emissions – immediately – without burdening them with financing and development obstacles. Our team's breadth of experience enables us to identify and develop unique solutions that improve our customers' competitive position.

Visit the Cambridge Energy Partners website

Cambridge Energy Partners logo

JustMilk

JustMilk consists of a US non-profit and a UK for-profit organisation developing the Nipple Shield Delivery System (NSDS), a novel medical device with the potential to improve the safety, efficacy, and access to life-saving medications, vitamins, and nutrients to breastfeeding infants globally. 

When worn by a mother during breastfeeding, the NSDS releases active pharmaceutical agents into milk which is then consumed by the infant. A wide range of medications and nutrients could be delivered to infants for treatment or prevention of conditions which may include diarrhoeal disease, HIV, malaria, or malnutrition.

With the NSDS, JustMilk aims to bridge a global drug delivery technology gap for breastfeeding infants, particularly in developing countries where it could overcome conventional administration challenges associated with limited availability of potable water, refrigeration, and medical care. JustMilk is currently seeking pharmaceutical partners.

Watch JustMilk in discussion with Luther Phillips

Visit the JustMilk website

JustMilk logo

SPIREA

SPIREA is a healthcare technology company that has developed a smart polymer platform for the controlled delivery of drug combinations to maximise the clinical impact of medicines.

The technology is based on biodegradable polymeric formulations of a combination of drugs for targeted and sustained release that will ultimately improve the efficacy and safety of treatments and patient compliance and comfort. This means a simpler, safer and more effective treatment for various diseases and a pioneering strategy in the management of diseases by combination therapy.

SPIREA aims to establish the polymer platform as a major player in the drug delivery space by partnering with pharmaceutical and biotech companies.

SPIREA logo